115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human safety, imaging and dosimetry of [(68(Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma
    Meeting Abstract

    Hofman, M. S.; Tran, B.; Feldman, D. R.; Pokorska-Bocci, A.; Pichereau, S.; Wessen, J.; Haskali, M. B.; Sparks, R.; Vlasyuk, O.; Galetic, I.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Haanen, Jbag; Schmidinger, M.; Staehler, M. D.; Goh, J. C.; Voog, E.; Climent, M. A.; George, S.; Burgents, J. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Hypoxia-inducible factor-2 alpha (HIF-2α) target activation and clinical outcomes in 942 patients with clear cell renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Kuo, F.; Knezevic, A.; Kotecha, R. R.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)
    Meeting Abstract

    Niazi, T.; Nguyen, P. L.; Williams, S.; Stockler, M. R.; Martin, A. J.; Horvath, L.; Thomas, H.; Sinikovic Zebic, D.; Roncolato, F.; Lim, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Meeting Abstract

    Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Meeting Abstract

    Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P. T.; Wagner, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Randomized trial of transperineal versus transrectal prostate biopsy to prevent infection complications
    Meeting Abstract

    Hu, J. C.; Vickers, A.; Allaf, M. E.; Ehdaie, B.; Cohen, A. J.; Ristau, B. T.; Green, D.; Han, M.; Rezaee, M.; Pavlovich, C. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures
    Meeting Abstract

    Freedland, S. J.; Mulhall, J.; Gleave, M.; De Giorgi, U.; Saad, F.; Rannikko, A.; Ivanova, J. I.; Nasr, A.; Reisman, A.; Ganguli, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save